#CancerAdvocacy #PatientVoices #HTA #tarlatamab #PatientExperience #CancerSupport #Imdelltra #SmallCellLungCancer #SCLC #PatientAdvocacy #CaregiverSupport #CancerAwareness #PublicFunding #AccessToCare #LungCancerCanada

タラタマブ（Imdelltra）、再発小細胞肺がんでFDA完全承認｜生存期間を5.3か月延長 | STELLANEWS.LIFE Amgenのタラタマブ（Imdelltra）が、広範期小細胞肺がんに対する第3相試験で全生存期間を有意に延長し、FDAの完全承認を取得。DLL3標的の二重特異性抗体として新たな治療選択肢に。

FDA grants full approval to Amgen’s Imdelltra (tarlatamab) for relapsed extensive-stage small cell lung cancer (ES-SCLC).

🔗 Full article: stellanews.life/technology_c...

#Imdelltra #Tarlatamab #Amgen #SCLC #Oncology #DLL3 #FDAApproval #Immunotherapy #ClinicalTrials

<em>Respirology Case Reports</em> | APSR Respiratory Medicine Journal | Wiley Online Library We reported a case of rapid brain atrophy and leukoencephalopathy development after treatment with tarlatamab. Patients with brain metastases, regardless of treatment history, may be at increased…

#Brain Atrophy and #Leukoencephalopathy Following #Tarlatamab: Case Report
onlinelibrary.wiley.com/doi/10.1002/...

Tarlatamab + Anti–PD-L1 Extends Survival in Extensive-stage small cell lung cancer - OncoDaily Tarlatamab plus anti–PD-L1 shows unprecedented survival in ES-SCLC, with median OS 25.3 months and favorable safety in the DeLLphi-303 trial.

Tarlatamab + Anti–PD-L1 Extends Survival in Extensive-stage small cell lung cancer

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Tarlatamab #SCLC #LungCancer

Early #Pseudoprogression After #Tarlatamab in Small-Cell #LungCancer: A Case Report
onlinelibrary.wiley.com/doi/10.1002/...

OS boost with tarlatamab in SCLC after platinum progression Patients with small-cell lung cancer who have progressed on platinum-based chemotherapy derive a significant survival benefit from treatment with tarlatamab.

From #ASCO25 - Patients with #SCLC who have progressed on platinum-based chemotherapy derive a significant survival benefit from treatment with #tarlatamab.

Full story 👉 buff.ly/kANl5G7

#OncSky #LungCancer #MedNews

Nuovo farmaco contro il tumore ai polmoni: -40% rischio morte Il tarlatamab di Amgen aumenta la sopravvivenza globale dei pazienti da 8,3 a circa 14 mesi

🔴 Nuovo farmaco contro il #tumore ai polmoni. Riduce del 40% il rischio di morte.
Il tarlatamab di Amgen aumenta la sopravvivenza globale dei pazienti da 8,3 a circa 14 mesi.
#salute #news #cancro #polmoni #tarlatamab
www.agi.it/salute/news/...

This study explores patient-reported outcomes #PROs for patients with previously treated #SCLC receiving #Tarlatamab, a bispecific T-cell engager binding #DLL3 and #CD3

@natureportfolio.nature.com

#Onco404 #Cancer #Kanser #LungCancer #ClinicalTrials #Immunotherapy #BispesificAntibody #MedSky

In this phase 1 substudy led by Dr. Anne Chiang, data suggests a shortened 6-8-hour outpatient monitoring after #tarlatamab cycle 1 doses was feasible with patient education. #SCLC
sciencedirect.com/science/arti...
@yaleschoolofmed.bsky.social

Happy to share our recent #ESMOOpen paper on the #safety and #feasibility of #outpatient administration of #tarlatamab as part of the #DeLLphi300 study providing evidence that support less intensive monitoring at initiation of therapy. #LCSM 🫁 #SCLC 😀

doi.org/10.1016/j.es...

Practical management of adverse events in patients receiving tarlatamab, a delta‐like ligand 3–targeted bispecific T‐cell engager immunotherapy, for previously treated small cell lung cancer Tarlatamab received accelerated approval from the US Food and Drug Administration for the treatment of patients with previously treated small cell lung cancer. This review summarizes the safety profi....

Guidelines for managing #tarlatamab - associated toxicities in #SCLC #lcam #lcsm

acsjournals.onlinelibrary.wiley.com/doi/10.1002/...

Amgen’s lung cancer treatment gets conditional approval - PharmaTimes IMDYLLTRA offers new hope for patients with extensive-stage small cell lung cancer

#oncology #lungcancer @amgen.bsky.social #lungcancertreatment #IMDYLLTRA #tarlatamab #extensivestagesmallcelllungcancer #ESSCLC #ESSCLCpatients #UK #MHRA #conditionalmarketingauthorisation #Smallcelllungcancer #SCLC #DeLLphi301study #objectiveresponserate
pharmatimes.com/news/amgens-...

2024 approvals: Summary of 14 new drugs/indications in #LungCancer by FDA

1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab (now SubQ)
9. #Ensartinib

#lcsm #OncSky #MedSky #Cancer